Xinan Qiao

127 Changle West Road
Xi'an, 710032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Corrigendum to "Targeting PHKA2 by Thymol alleviates sepsis induced cardiomyocyte pyroptosis via FOXA1/KLF4-mediated macrophage polarization" [Phytomedicine (2026) 159:158480/PHYMED 158480].

Corrigendum to "Targeting PHKA2 by Thymol alleviates sepsis induced cardiomyocyte pyroptosis via FOXA1/KLF4-mediated macrophage polarization" [Phytomedicine (2026) 159:158480/PHYMED 158480].

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: July 28, 2026

Targeting PHKA2 by Thymol alleviates sepsis induced cardiomyocyte pyroptosis via FOXA1/KLF4-mediated macrophage polarization.

Targeting PHKA2 by Thymol alleviates sepsis induced cardiomyocyte pyroptosis via FOXA1/KLF4-mediated macrophage polarization.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: February 02, 2026

H2S Click Delivery: Responsive Release for Multidimensional Therapy of Thoracic Aortic Dissection.

H2S Click Delivery: Responsive Release for Multidimensional Therapy of Thoracic Aortic Dissection.

Journal: Advanced healthcare materials

Published: July 31, 2025

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress.

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress.

Journal: Journal of experimental & clinical cancer research : CR

Published: October 17, 2024

The m6A modification of SOX18 leads to increased PTX3 and cardiomyocyte pyroptosis in sepsis-induced cardiomyopathy.

The m6A modification of SOX18 leads to increased PTX3 and cardiomyocyte pyroptosis in sepsis-induced cardiomyopathy.

Journal: Theranostics

Published: September 17, 2024

ACE2 deficiency inhibits thoracic aortic dissection by enhancing SIRT3 mediated inhibition of inflammation and VSCMs phenotypic switch.

ACE2 deficiency inhibits thoracic aortic dissection by enhancing SIRT3 mediated inhibition of inflammation and VSCMs phenotypic switch.

Journal: Molecular medicine (Cambridge, Mass.)

Published: June 25, 2024

The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia.

The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia.

Journal: Cancer research

Published: September 06, 2023

Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.

Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.

Journal: Biochemical pharmacology

Published: April 11, 2023

Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.

Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.

Journal: Cells

Published: August 04, 2022

Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia.

Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia.

Journal: Biochemical pharmacology

Published: August 03, 2022

c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia.

c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia.

Journal: Apoptosis : an international journal on programmed cell death

Published: July 10, 2022

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML.

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML.

Journal: Blood cancer journal

Published: April 02, 2021

Showing 1-12 of 16

Last Updated: 09/26/2026